Journal of the Formosan Medical Association
Volume 105, Issue 9 , Pages 765-769 , 2006

Successful Treatment of Intractable Hemothorax with Recombinant Factor VIIa in a Nonhemophilic Patient

  • Yu-Feng Wei

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei
    • Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan
    • ,
  • Chao-Chi Ho

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei
    • Department of Emergency Medicine, National Taiwan University Hospital, Taipei
    • Corresponding Author InformationCorrespondence to: Dr Chao-Chi Ho, Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shang South Road, Taipei 100, Taiwan
    • ,
  • Ming-Tzer Lin

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei
    • ,
  • Ang Yuan

      Affiliations

    • Department of Emergency Medicine, National Taiwan University Hospital, Taipei
    • ,
  • Chong-Jen Yu

      Affiliations

    • Department of Internal Medicine, National Taiwan University Hospital, Taipei

Received 13 June 2005 ,Revised 15 September 2005 ,Accepted 1 November 2005.

References 

  1. Lisman T , De Groot PG . Mechanism of action of recombi-nant factor VIIa . J Thromb Haemost . 2003;1:1138–1139
  2. Butenas S , Brummel KE , Branda RF , et al.   Mechanism of factor VIIa-dependent coagulation in hemophilia blood . Blood . 2002;99:923–930
  3. Hoffman M , Monroe DM . The action of highdose factor VIIa (FVIIa) in a cell-based model of hemostasis . Semin Hematol . 2001;38:6–9
  4. Roberts HR , Monroe DM , Hoffman M . Safety profile of recombinant factor VIIa . Semin Hematol . 2004;41:101–108
  5. Romero-Castro R , Jimenez-Saenz M , Pellicer-Bautista F , et al.   Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices . Clin Gastroenterol Hepatol . 2004;2:78–84
  6. Light RW . Hemothorax . In: Pleural Disease . 4th edition. Philadelphia: Lippincott Williams and Wilkins; 2001;p. 320–326
  7. Kessel B , Alfici R , Ashkenazi I , et al.   Massive hemothorax caused by intercostal artery bleeding: selective embolization may be an alternative to thoracotomy in selected patients . Thorac Cardiovasc Surg . 2004;52:234–236
  8. Poon MC . Use of recombinant factor VIIa in hereditary bleeding disorders . Curr Opin Hematol . 2001;8:312–318
  9. Erhardtsen E . Pharmacokinetics of recombinant activated factor VII (rFVIIa) . Semin Thromb Hemost . 2000;26:385–391
  10. Hedner U . Dosing with recombinant factor VIIa based on current evidence . Semin Hematol . 2004;41:35–39
  11. Gabriel DA , Carr M , Roberts HR . Monitoring coagulation and the clinical effects of recombinant factor VIIa . Semin Hematol . 2004;41:20–24
  12. Caldwell SH , Chang C , Macik BG . Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials . Hepatology . 2004;39:592–598
  13. Goodnough LT . Experiences with recombinant human factor VIIa in patients with thrombocytopenia . Semin Hematol . 2004;41:25–29
  14. Almeida AM , Khair K , Hann I , et al.   The use of recombi-nant factor VIIa in children with inherited platelet function disorders . Br J Haematol . 2003;121:477–481
  15. Martinowitz U , Kenet G , Lubetski A , et al.   Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma . Can J Anaesth . 2002;49:S15–S20
  16. Tanaka KA , Waly AA , Cooper WA , et al.   Treatment of excessive bleeding in Jehovah's witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven) . Anesthesiology . 2003;98:1513–1515
  17. Ahonen J , Jokela R . Recombinant factor VIIa for life-threatening post-partum haemorrhage . Br J Anaesth . 2005;94:592–595
  18. Pastores SM , Papadopoulos E , Voigt L , et al.   Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa . Chest . 2003;124:2400–2403
  19. Mayer SA , Brun NC , Begtrup K , et al.   Recombinant activated factor VIIa for acute intracerebral hemorrhage . N Engl J Med . 2005;352:777–785
  20. Deveras RA , Kessler CM . Reversal of warfarin induced excessive anticoagulation with recombinant human factor VIIa concentrate . Ann Intern Med . 2002;137:884–888
  21. O'Connell NM , Perry DJ , Hodgson AJ , et al.   Recombinant FVIIa in the management of uncontrolled hemorrhage . Transfusion . 2003;43:1711–1716
  22. Abshire T , Kenet G . Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors . J Thromb Haemost . 2004;2:899–909

PII: S0929-6646(09)60206-0

doi: 10.1016/S0929-6646(09)60206-0

Journal of the Formosan Medical Association
Volume 105, Issue 9 , Pages 765-769 , 2006

Article Tools